Relentlessly Focused on Liver Disease
Exploiting the power of bile acid modulation to pursue new potential treatment options to improve the lives of people living with liver disease. Discover More
Targeted Expertise.
Brighter Outcomes.
There are currently no approved drug therapies for Progressive Familial Intrahepatic Cholestasis (PFIC). Our goal is to change that.
Backed by Deep Knowledge of IBAT Inhibition
Dedicated to the development of novel bile acid modulators to relieve the pain and suffering of people living with orphan liver diseases.
Better Pediatric Liver Solutions are in Development
Our programs are designed to target and enable normal bile acid level modulation and treat diseases and disorders associated with irregularities in bile acid biology.
Albireo's A4250 is a potent and selective IBAT inhibitor
We are developing A4250 initially to treat patients with PFIC, a rare genetic liver disease.
A Leader in Bile Acid Biology and the Development of Novel Bile Acid Modulators
We leverage our expertise in bile acid modulation with the goal of bringing potentially transformative medicines to patients. For more information, read Albireo's Corporate Backgrounder.
